Company Profile
Cartesian Therapeutics Stock Price, News & Analysis
- Ticker:
- RNAC
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
8.76 USD (+4.91%)
Close
Last updated: August 6, 2026
188M USD
Market cap
Why the stock is moving
The latest monitored company update is “Cartesian Therapeutics Announces New Employment Inducement Grants.” The corresponding closing-price reaction is not yet available.
Company overview
RNA CAR-T for Autoimmune Disease
Cartesian Therapeutics develops cell therapies for autoimmune diseases using mRNA-engineered CAR-T cells. Its approach is designed to produce controlled, temporary CAR expression and permit outpatient repeat dosing without preconditioning chemotherapy.
Descartes-08 in Myasthenia Gravis
Descartes-08 is an autologous BCMA-directed CAR-T therapy in the Phase 3 AURORA trial for acetylcholine-receptor-antibody-positive myasthenia gravis. The study compares six once-weekly outpatient infusions with placebo on top of standard care.
Myositis Programs
The Phase 2 TRITON trial is evaluating Descartes-08 in adults with dermatomyositis and antisynthetase syndrome. The Phase 1/2 HELIOS study extends the program into children and young adults with juvenile dermatomyositis and other autoimmune diseases.
Future catalysts
Evaluation of the first 10 patients in the Phase 2 TRITON trial to determine the path to a pivotal myositis study.
Recent news
- 01
Cartesian Therapeutics Announces New Employment Inducement Grants
Source: Cartesian Therapeutics
- 02
Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Source: Cartesian Therapeutics
- 03
Cartesian Therapeutics Announces New Employment Inducement Grant
Source: Cartesian Therapeutics
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Cartesian Therapeutics (RNAC)?
Cartesian Therapeutics (RNAC) most recently closed at 8.76 USD, a +4.91% move versus the previous session.
What is the market cap of Cartesian Therapeutics (RNAC)?
Cartesian Therapeutics currently has a market capitalization of 188M USD on BioPharmSignal.
What does Cartesian Therapeutics do?
RNA CAR-T for Autoimmune Disease Cartesian Therapeutics develops cell therapies for autoimmune diseases using mRNA-engineered CAR-T cells. Its approach is designed to produce controlled, temporary CAR expression and permit outpatient repeat dosing without preconditioning chemotherapy. Descartes-08 in Myasthenia Gravis Descartes-08 is an autologous...
On which exchange is RNAC stock listed?
Cartesian Therapeutics (RNAC) is associated with NASDAQ, United States, Biopharma.
What is CAR-T?
RNA CAR-T for Autoimmune Disease Cartesian Therapeutics develops cell therapies for autoimmune diseases using mRNA-engineered CAR-T cells.
Which conditions is Cartesian Therapeutics targeting with CAR-T?
RNA CAR-T for Autoimmune Disease Cartesian Therapeutics develops cell therapies for autoimmune diseases using mRNA-engineered CAR-T cells. Its approach is designed to produce controlled, temporary CAR expression and permit outpatient repeat dosing without preconditioning chemotherapy. Descartes-08 in Myasthenia Gravis Descartes-08 is an autologous...
How does Cartesian Therapeutics describe recent progress with CAR-T?
Evaluation of the first 10 patients in the Phase 2 TRITON trial to determine the path to a pivotal myositis study.
What is Autoimmune?
RNA CAR-T for Autoimmune Disease Cartesian Therapeutics develops cell therapies for autoimmune diseases using mRNA-engineered CAR-T cells.